Disulfiram combined with copper supplementation is in phase II trials for metastatic breast cancer that has progressed despite conventional systemic and/or locoregional therapies (NCT03323346), as well as for CTC_EMT-positive, refractory, metastatic hormone receptor-positive, HER-2-negative breast cancer (NCT04265274). Here, NR4A1 is linked to breast cancer.